PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
20042183-7	2010	These data strongly suggest that DAB(389)IL-2 specifically targeted myelin protein-activated CD4(+) T cells and strengthens the argument for the use of DAB(389)IL-2 in treatment strategies for MS.	diazobenzenesulfonic acid	33-36	CD4 antigen	Mus musculus	93-96	
20042183-6	2010	DAB(389)IL-2 also significantly reduced the number of CD4(+), CD8(+), CD25(+), TCRgammadelta(+) phenotype and CD11b(+) macrophages/microglia within spinal cord lesions.	diazobenzenesulfonic acid	0-3	CD4 antigen	Mus musculus	54-57